William L. Moore
All posts from William L. Moore
William L. Moore in Insider trading,

With Solid Growth And Strong Pipeline, Argus Is Positive On Celgene's Long-Term Prospects

Argus analyst David Toung shared a look into Focus List-selected Celgene Corporation , reiterating a Buy rating and $155 price target.

The expert argued that the company has not only managed to generate robust growth from its pharmaceuticals portfolio, but that a strong new product pipeline should support future growth – and investors will get an insight on it in the September 29 New York meeting.

While multiple myeloma drug Revlimid continues to be the No. 1 revenue contributor, plaque psoriasis and psoriatic arthritis treatment Otezla, with its triple-digit growth rate, might soon become another growth driver, Toung added.